Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

NCRI 2019 | CAR T-cell therapy toxicities in B-cell lymphomas

Jakub Svoboda • 8 Nov 2019
NCRI 2019
B-Cell Lymphoma Lymphoma

Jakub Svoboda, MD, University of Pennsylvania, Philadelphia, PA, talks about CAR T-cell therapy toxicities in B-cell lymphomas. Recorded at the 2019 National Cancer Research Institute (NCRI) Annual Cancer Conference, in Glasgow, UK.
For more information about the NCRI Cancer Conference, visit https://conference.ncri.org.uk.

More from Jakub Svoboda

Combined chemotherapy and consolidative radiation versus chemotherapy alone in early-stage cHL
3:21
Combined chemotherapy and consolidative radiation versus chemotherapy alone in early-stage cHL
Jakub Svoboda • 7 Dec 2025
huCART19-IL18 in patients with CLL/SLL or RT after prior BTK inhibitor and venetoclax exposure
3:36
huCART19-IL18 in patients with CLL/SLL or RT after prior BTK inhibitor and venetoclax exposure
Jakub Svoboda • 7 Dec 2025
BrECADD versus BEACOPP in advanced HL: a German Hodgkin Study Group investigation
1:37
BrECADD versus BEACOPP in advanced HL: a German Hodgkin Study Group investigation
Jakub Svoboda • 2 Jun 2024
Specifying which patients should undergo cardiovascular surveillance following lymphoma treatment
2:13
Specifying which patients should undergo cardiovascular surveillance following lymphoma treatment
Jakub Svoboda • 2 Jun 2024

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Jakub Svoboda • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Jakub Svoboda • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Jakub Svoboda • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Jakub Svoboda • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals